Ischemic stroke (IS) is a statistically significant cause of morbidity and mortality not only in terms of acute management
following their occurrence, as well as in terms of follow-up care, which should prevent complications. Managing
the hyperacute stage must be followed by determining the etiopathogenesis in each individual patient in order to reduce
the risk of recurrence to the greatest extent possible. Recurrence occurs in up to 10% in the first week after TIA
or mild IS. This article aims to inform about the possibilities of secondary prevention of IS of atherothrombotic (noncardioembolic)
and cardioembolic etiologies.